Oncology Drug Reference Sheet: Venetoclax

Venetoclax (Venclexta^®) was approved by the U.S. Food and Drug Administration (FDA) on May 15, 2019, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a single agent or in combination therapy. Previously, it had been approved in late 2018 for use in combination therapy for acute myeloid leukemia (AML) in older adults or those with significant comorbidities.